中国百日咳行动计划专家共识

2021-04-10 中华预防医学会 中华实用儿科临床杂志.2021.36(11):801-810.

自20世纪80年代以来,一些百日咳白喉破伤风联合疫苗接种率高的国家陆续发生了百日咳流行或局部暴发,被称之为百日咳再现。近年来,我国一些省份也陆续出现百日咳疫情大幅回升,引起各方高度关注。为此,中华预防

中文标题:

中国百日咳行动计划专家共识

发布机构:

中华预防医学会

发布日期:

2021-04-10

简要介绍:

自20世纪80年代以来,一些百日咳白喉破伤风联合疫苗接种率高的国家陆续发生了百日咳流行或局部暴发,被称之为百日咳再现。近年来,我国一些省份也陆续出现百日咳疫情大幅回升,引起各方高度关注。为此,中华预防医学会参考“全球百日咳行动计划”工作模式,发起了“中国百日咳行动计划”,并组织相关专家研究形势,分析问题。在对国内外百日咳研究最新进展、流行趋势和免疫策略进行讨论和研究的基础上,形成本专家共识,以期为指导当前中国百日咳防控工作提供帮助。

 

相关资料下载:
[AttachmentFileName(sort=1, fileName=中国百日咳行动计划专家共识_徐爱强.pdf)] GetToolGuiderByIdResponse(projectId=1, id=7a1ca1c002092694, title=中国百日咳行动计划专家共识, enTitle=, guiderFrom=中华实用儿科临床杂志.2021.36(11):801-810., authorId=0, author=, summary=自20世纪80年代以来,一些百日咳白喉破伤风联合疫苗接种率高的国家陆续发生了百日咳流行或局部暴发,被称之为百日咳再现。近年来,我国一些省份也陆续出现百日咳疫情大幅回升,引起各方高度关注。为此,中华预防, cover=https://img.medsci.cn/202158/1620485730928_2020535.jpg, journalId=0, articlesId=null, associationId=174, associationName=中华预防医学会, associationIntro=中华预防医学会是全国公共卫生预防医学领域的科技工作者自愿组成并依法在民政部登记注册的非营利性、公益性、学术性法人社团,是全国性学术团体,是发展我国预防医学科学技术和预防医学事业的重要社会力量。, copyright=0, guiderPublishedTime=Sat Apr 10 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<div class="one_info2" style="color: #373737;"> <div id="all_content"> <div class="editor_mirror editor_mirror_del"> <p>自20世纪80年代以来,一些百日咳白喉破伤风联合疫苗接种率高的国家陆续发生了百日咳流行或局部暴发,被称之为百日咳再现。近年来,我国一些省份也陆续出现百日咳疫情大幅回升,引起各方高度关注。为此,中华预防医学会参考&ldquo;全球百日咳行动计划&rdquo;工作模式,发起了&ldquo;中国百日咳行动计划&rdquo;,并组织相关专家研究形势,分析问题。在对国内外百日咳研究最新进展、流行趋势和免疫策略进行讨论和研究的基础上,形成本专家共识,以期为指导当前中国百日咳防控工作提供帮助。</p> </div> </div> </div> <div class="box_info" style="color: #373737;">&nbsp;</div>, tagList=[TagDto(tagId=13304, tagName=百日咳)], categoryList=[CategoryDto(categoryId=12, categoryName=呼吸, tenant=100), CategoryDto(categoryId=35, categoryName=预防与公卫, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=13304, guiderKeyword=百日咳, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=0, guiderRegion=3, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=5110, appHits=134, showAppHits=0, pcHits=929, showPcHits=4973, likes=0, shares=16, comments=12, approvalStatus=1, publishedTime=Sat May 08 23:28:46 CST 2021, publishedTimeString=2021-04-10, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=qiushida2, createdTime=Sat May 08 22:55:44 CST 2021, updatedBy=2020535, updatedName=qiushida2, updatedTime=Sat Jan 06 19:55:03 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=中国百日咳行动计划专家共识_徐爱强.pdf)])
中国百日咳行动计划专家共识_徐爱强.pdf
下载请点击:
评论区 (10)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1237975, encodeId=be75123e97533, content=学子, beContent=null, objectType=guider, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1bdd5596550, createdName=清漩, createdTime=Thu Aug 11 05:07:38 CST 2022, time=2022-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1011680, encodeId=3bf41011680d1, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b241692435, createdName=xyzhang97, createdTime=Thu Aug 26 12:43:54 CST 2021, time=2021-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=977000, encodeId=8bb79e70009d, content=十分有用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=29885466350, createdName=ms6000001363465429, createdTime=Sat Jun 26 09:44:00 CST 2021, time=2021-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=965853, encodeId=bc159658537b, content=好共识!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Sat May 15 15:37:58 CST 2021, time=2021-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=964927, encodeId=abf896492e8b, content=好共识!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Wed May 12 15:54:34 CST 2021, time=2021-05-12, status=1, ipAttribution=)]
    2022-08-11 清漩

    学子

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1237975, encodeId=be75123e97533, content=学子, beContent=null, objectType=guider, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1bdd5596550, createdName=清漩, createdTime=Thu Aug 11 05:07:38 CST 2022, time=2022-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1011680, encodeId=3bf41011680d1, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b241692435, createdName=xyzhang97, createdTime=Thu Aug 26 12:43:54 CST 2021, time=2021-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=977000, encodeId=8bb79e70009d, content=十分有用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=29885466350, createdName=ms6000001363465429, createdTime=Sat Jun 26 09:44:00 CST 2021, time=2021-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=965853, encodeId=bc159658537b, content=好共识!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Sat May 15 15:37:58 CST 2021, time=2021-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=964927, encodeId=abf896492e8b, content=好共识!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Wed May 12 15:54:34 CST 2021, time=2021-05-12, status=1, ipAttribution=)]
    2021-08-26 xyzhang97

    感谢分享

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1237975, encodeId=be75123e97533, content=学子, beContent=null, objectType=guider, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1bdd5596550, createdName=清漩, createdTime=Thu Aug 11 05:07:38 CST 2022, time=2022-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1011680, encodeId=3bf41011680d1, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b241692435, createdName=xyzhang97, createdTime=Thu Aug 26 12:43:54 CST 2021, time=2021-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=977000, encodeId=8bb79e70009d, content=十分有用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=29885466350, createdName=ms6000001363465429, createdTime=Sat Jun 26 09:44:00 CST 2021, time=2021-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=965853, encodeId=bc159658537b, content=好共识!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Sat May 15 15:37:58 CST 2021, time=2021-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=964927, encodeId=abf896492e8b, content=好共识!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Wed May 12 15:54:34 CST 2021, time=2021-05-12, status=1, ipAttribution=)]
    2021-06-26 ms6000001363465429

    十分有用

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1237975, encodeId=be75123e97533, content=学子, beContent=null, objectType=guider, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1bdd5596550, createdName=清漩, createdTime=Thu Aug 11 05:07:38 CST 2022, time=2022-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1011680, encodeId=3bf41011680d1, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b241692435, createdName=xyzhang97, createdTime=Thu Aug 26 12:43:54 CST 2021, time=2021-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=977000, encodeId=8bb79e70009d, content=十分有用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=29885466350, createdName=ms6000001363465429, createdTime=Sat Jun 26 09:44:00 CST 2021, time=2021-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=965853, encodeId=bc159658537b, content=好共识!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Sat May 15 15:37:58 CST 2021, time=2021-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=964927, encodeId=abf896492e8b, content=好共识!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Wed May 12 15:54:34 CST 2021, time=2021-05-12, status=1, ipAttribution=)]
    2021-05-15 jyzxjiangqin

    好共识!

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1237975, encodeId=be75123e97533, content=学子, beContent=null, objectType=guider, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1bdd5596550, createdName=清漩, createdTime=Thu Aug 11 05:07:38 CST 2022, time=2022-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1011680, encodeId=3bf41011680d1, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b241692435, createdName=xyzhang97, createdTime=Thu Aug 26 12:43:54 CST 2021, time=2021-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=977000, encodeId=8bb79e70009d, content=十分有用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=29885466350, createdName=ms6000001363465429, createdTime=Sat Jun 26 09:44:00 CST 2021, time=2021-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=965853, encodeId=bc159658537b, content=好共识!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Sat May 15 15:37:58 CST 2021, time=2021-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=964927, encodeId=abf896492e8b, content=好共识!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Wed May 12 15:54:34 CST 2021, time=2021-05-12, status=1, ipAttribution=)]
    2021-05-12 jyzxjiangqin

    好共识!

    0

拓展阅读

2018 ACIP建议:百日咳,破伤风和白喉的疫苗预防

免疫实践咨询委员会(ACIP,Advisory Committee on Immunization Practices) · 2018-04-07

百日咳诊疗方案(2023 年版)

中华人民共和国国家卫生健康委员会 · 2023-12-28